Functional class in children

Size: px
Start display at page:

Download "Functional class in children"

Transcription

1 Functional class in children WHO-FC versus Panama Pediatric FC Astrid E Lammers Paediatric Cardiology, Münster University Hospital Astrid.Lammers@ukmuenster.de

2 Disclosures Consulting activity for Actelion No other conflict of interests. 2

3 Why do we need a functional classification? Escalation of therapy Intervention/ Operation Palliative care Hospice 3

4 Why do we need a functional classification? Evaluation of ability of physical performance/ functioning in daily life Comparison of patients to healthy peers Monitoring following a therapeutic intervention ( goal-orientated therapy ) Evaluate prognosis and risk stratification for the individual patient Group patients with comparable status of disease for therapeutic guidance and studies 4

5 Functional class prognosis McLaughlin VV. Circulation 2002;106:

6 Change of functional class Impact on Prognosis Barst RJ. Chest 2013

7 Ploegstra IJC, 184 (2015)

8 Conventional functional classifications NYHA WHO Not very specific and easy to apply particularly in young children 8

9 FC I-IV 5 age groups 9 Lammers AE. Pulm Circ. 2011; 1(2):

10 Introduction of 3 new categories 1. Motorical developmental milestones Regression of already learned motorical abilities 10

11 Panama classification, PVRI pediatric taskforce, Panama Lammers AE. Pulm Circ. 2011; 1(2):

12 Milestones of motorical develoment: 0-15/12 12

13 Introduction of 3 new categories 1. Motorical developmental milestones Regression of already learned motorical abilities 2. Growth and physical development 13

14 Functional class I II III IV

15 ? Functional class I II III IV

16 UK Pulmonary Hypertension Service for Children 39 IPAH on continuous iv epoprostenol IPAH z-score for weight from -1,6-1,2 Moledina, Heart. 2010;96: Lammers AE, Heart 2007;93:

17 Panama classification, PVRI pediatric taskforce, Panama 2011 Lammers AE. Pulm Circ. 2011; 1(2):

18 18 Ploegstra MJ et al. Lancet, Lancet Respir Med 2016; 4:

19 19 Ploegstra MJ et al. Lancet, Lancet Respir Med 2016; 4:

20 Introduction of 3 new categories 1. Motorical developmental milestones Regression of already learned motorical abilities 2. Growth and physical development 3. School/ Kindergarten attendance, participation in sports/pe 20

21 21

22 22

23 Panama classification, PVRI pediatric taskforce, Panama 2011 Lammers AE. Pulm Circ. 2011; 1(2):

24 Limitations of Panama classifcation Parameters are not objective Overlap between functional classes School and Kindergarten attendence is dependent on many factors: type of school (inclusion/ special needs) distance to school and mode of transport family structure Actual school attendance difficult to quantify (?diary) Syndromatic children or children with motordevelopmental delay may not be properly reflected in this classification. Not validated - First use in clinical trial Tomorrow Study: PediaTric Use Of Macicentan to Delay Disease progression in PAH Worlwide. 24

25 Discussion for a revised paediatric classification More specific? add height centiles/ z-scores Absolute values or centile change? Define cut-off values? Growth compromise when negative z-score? Severe growth compromise z >-2? Increase in strength of FC by combining other tools reflecting exercise capacity and physical functioning in daily life: e.g accelerometry 25

26 Time for a revision of the Panama classification? 26

27 Peak systo CPET Functional class MRI variables PA compliance/ distensibility 27

28 28

29 Nice

30 Bedankt vor uw aandacht! Contact:

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University

More information

MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)

MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial

More information

STARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:

STARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125: STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial

More information

Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension

Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension 5 December 2011 EMA/CHMP/213972/2010 Committee for Medicinal Products for Human use (CHMP) Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of

More information

Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry

Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification

More information

Disclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline

Disclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar

More information

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest

More information

Intravenous Therapies for Pulmonary Hypertensive Vascular Disease. Intravenous Treatment for PAH: Past, Present and Future 3/10/2012

Intravenous Therapies for Pulmonary Hypertensive Vascular Disease. Intravenous Treatment for PAH: Past, Present and Future 3/10/2012 Intravenous Therapies for Pulmonary Hypertensive Vascular Disease Robyn J Barst MD Professor Emeritus Columbia University New York, NY March 1 th 212 Presented By: Erika Berman Rosenzweig, MD Dr. Robyn

More information

In focus The paediatric PAH population Clinicians Perspectives

In focus The paediatric PAH population Clinicians Perspectives In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire

More information

Θεραπεία με βάση τη βαρύτητα ή εξαρχής επιθετική συνδυαστική θεραπεία. Φραντζέσκα Φραντζεσκάκη Πνευμονολόγος-Εντατικολόγος ΠΓΝ «ΑΤΤΙΚΟΝ»

Θεραπεία με βάση τη βαρύτητα ή εξαρχής επιθετική συνδυαστική θεραπεία. Φραντζέσκα Φραντζεσκάκη Πνευμονολόγος-Εντατικολόγος ΠΓΝ «ΑΤΤΙΚΟΝ» Θεραπεία με βάση τη βαρύτητα ή εξαρχής επιθετική συνδυαστική θεραπεία Φραντζέσκα Φραντζεσκάκη Πνευμονολόγος-Εντατικολόγος ΠΓΝ «ΑΤΤΙΚΟΝ» S.Gaine and V.McLaughlin, Eur Respi Rev 2017;26 Ultimate goal of

More information

Raymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.

Raymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M. http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled

More information

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007 Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed

More information

Pulmonary Hypertension: Follow-up in adolescence and adults

Pulmonary Hypertension: Follow-up in adolescence and adults Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany

More information

Neonatal and Pediatric Pulmonary Vascular Disease

Neonatal and Pediatric Pulmonary Vascular Disease Neonatal and Pediatric Pulmonary Vascular Disease Emma Olson, MS, ARNP Pediatric Cardiology Nurse Practitioner Canadian Respiratory Conference April 14, 2018 Financial Interest Disclosure (over the past

More information

Role of Combination PAH Therapies

Role of Combination PAH Therapies Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical

More information

THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU

THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU Cardiology Dept. Rambam Health Care Campus Rappaport Faculty of Medicine Technion, Israel Why the Right Ventricle? Pulmonary hypertension (PH) Right

More information

The challenges in paediatric pulmonary arterial hypertension

The challenges in paediatric pulmonary arterial hypertension REVIEW PULMONARY ARTERIAL HYPERTENSION The challenges in paediatric pulmonary arterial hypertension Maurice Beghetti 1 and Rolf M.F. Berger 2 Affiliations: 1 Paediatric Cardiology Unit, Children s University

More information

Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies

Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.

More information

Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON

Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac

More information

TREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650

TREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**

More information

Paediatric PAH in the current era

Paediatric PAH in the current era Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The

More information

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of

More information

Pulmonary veno-occlusive disease

Pulmonary veno-occlusive disease Disclosure Objectives Pulmonary veno-occlusive disease Tilman Humpl The Hospital for Sick Children University of Toronto, Canada Advisor/Research Grants Actelion Pfizer Historical aspects Epidemiology/Genetics

More information

Clinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88

Clinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88 Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Therapeutic approaches in P(A)H and the new ESC Guidelines

Therapeutic approaches in P(A)H and the new ESC Guidelines Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium

More information

Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension

Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension [ Original Research Pulmonary Vascular Disease ] Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension Mark-Jan Ploegstra, MD ; Sanne Arjaans, BSc ; Willemijn M.

More information

Pulmonary Hypertension Associated with Congenital Heart Disease. Amiram Nir Hadassah, Jerusalem

Pulmonary Hypertension Associated with Congenital Heart Disease. Amiram Nir Hadassah, Jerusalem Pulmonary Hypertension Associated with Congenital Heart Disease Amiram Nir Hadassah, Jerusalem Disclosure Honoraria - Actelion Research grants form Actelion The Nice Classification (2013) Blok et al. Expert

More information

Therapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics

Therapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics 1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary

More information

Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort

Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort Robert Schilz, DO, PhD, FCCP Medical Director, Lung Transplantation and Pulmonary Vascular Disease

More information

Objectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease

Objectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)

More information

Pulmonary Hypertension in 2012

Pulmonary Hypertension in 2012 Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of

More information

The Case of Lucia Nazzareno Galiè, M.D.

The Case of Lucia Nazzareno Galiè, M.D. The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical

More information

Inhaled Nitric Oxide Beyond the Evidence- Children

Inhaled Nitric Oxide Beyond the Evidence- Children Critical Care Canada Forum, Toronto 2014 Inhaled Nitric Oxide Beyond the Evidence- Children Ian Adatia, Pediatric Pulmonary Hypertension Service and Cardiac Intensive Care Unit, Stollery Children s Hospital,

More information

IV PGI2 vs. Inhaled PGI2 in chronic lung disease

IV PGI2 vs. Inhaled PGI2 in chronic lung disease Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has

More information

The Sildenafil Controversy

The Sildenafil Controversy The Sildenafil Controversy Chronology European Development Revatio (Sildenafil) Orphan Drug designation: 03.12.2003 & 27.02.2007 Paediatric Investigation Plan: 17.03.2010 Marketing Authorisation in EU:

More information

NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension

NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension Respiratory Medicine (2007) 101, 69 75 NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension Rogerio Souza a,b,c,, Carlos Jardim a, Caio Julio Cesar Fernandes a, Monica Silveira

More information

Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension

Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,

More information

ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO

ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support

More information

The Case of Marco Nazzareno Galiè, M.D.

The Case of Marco Nazzareno Galiè, M.D. The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical

More information

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic

More information

Annual Congress of the European Society of Cardiology Munich, August

Annual Congress of the European Society of Cardiology Munich, August Annual Congress of the European Society of Cardiology Munich, August 26 2012 Gas exchange measurements during exercise show early pulmonary arterial hypertension in scleroderma patients Daniel Dumitrescu,

More information

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy

More information

Tadalafil for the Treatment of Pulmonary Arterial Hypertension

Tadalafil for the Treatment of Pulmonary Arterial Hypertension Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004

More information

Φαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία

Φαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία 37 ο Πανελλήνιο Καρδιολογικό Συνέδριο Αθήνα, Οκτώβριος 2016 k Φαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό

More information

Oral Therapies for Pulmonary Arterial Hypertension

Oral Therapies for Pulmonary Arterial Hypertension Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives

More information

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension REVIEW 6MWD IN PAH TRIALS The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Sean Gaine 1 and Gérald Simonneau 2 Affiliations: 1 National Pulmonary Hypertension

More information

National Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008

National Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008 Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.

More information

Report on New Patented Drugs - Remodulin

Report on New Patented Drugs - Remodulin Report on New Patented Drugs - Remodulin June 06 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB

More information

ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH)

ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH) Aristotle University of Thessaloniki Cardiology Clinic, AHEPA Hospital ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH) Charalampos I. Karvounis, MD Professor of Cardiology Aristotle

More information

Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension

Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension CHEST Original Research PULMONARY VASCULAR DISEASE Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension Malcolm M. Bersohn, MD, PhD ; Michelle P. Turner, MS ; Glenna L.

More information

2012 CADTH Symposium. April 2012

2012 CADTH Symposium. April 2012 2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation

More information

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry CHEST Original Research PULMONARY VASCULAR DISEASE Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry Robyn J. Barst, MD ;

More information

Real-world experience with riociguat in CTEPH

Real-world experience with riociguat in CTEPH Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International

More information

Pulmonary Arterial Hypertension: The Approach to Management in 2019

Pulmonary Arterial Hypertension: The Approach to Management in 2019 Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical

More information

Interested party (Organisations or individuals) that commented on the draft Guideline as released for consultation

Interested party (Organisations or individuals) that commented on the draft Guideline as released for consultation European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 October 2009 Doc. Ref. EMEA/CHMP/EWP/582423/2009 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON THE CLINICAL

More information

Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH

Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Javier Jimenez MD PhD FACC Director, Advanced Heart Failure and Pulmonary Hypertension Miami Cardiac & Vascular Institute

More information

Untreated idiopathic pulmonary arterial hypertension

Untreated idiopathic pulmonary arterial hypertension Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,

More information

Treatment of Paediatric Pulmonary Hypertension

Treatment of Paediatric Pulmonary Hypertension Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships

More information

General awareness of the rare and devastating

General awareness of the rare and devastating Eur Respir Rev 2010; 19: 118, 331 339 DOI: 10.1183/09059180.00008510 CopyrightßERS 2010 REVIEW Issues related to the management and therapy of paediatric pulmonary hypertension I. Schulze-Neick* and M.

More information

Pulmonary hypertension; does gender matter?

Pulmonary hypertension; does gender matter? Pulmonary hypertension; does gender matter? Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it Galiè N et al. European Heart Journal (2009) 30, 2493 2537 Pulmonary Hypertension

More information

Understanding Complex Pulmonary Hypertension through Advanced Hemodynamics

Understanding Complex Pulmonary Hypertension through Advanced Hemodynamics Understanding Complex Pulmonary Hypertension through Advanced Hemodynamics Franz Rischard, DO, MS Director, Pulmonary Hypertension Program Assistant Professor of Medicine University of Arizona Lillian

More information

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH Effectively treating patients with pulmonary hypertension: The next chapter Stuart Rich, M.D. Hemodynamic Progression of PAH Preclinical Symptomatic/ Stable Pulmonary Pressure Progressive/ Declining Level

More information

Although idiopathic pulmonary arterial hypertension. Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines

Although idiopathic pulmonary arterial hypertension. Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines Vallerie V. McLaughlin, MD, FCCP; Kenneth W. Presberg, MD, FCCP; Ramona L. Doyle, MD, FCCP; Steven H. Abman,

More information

Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension.

Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension. Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension. Mark K. Friedberg, MD No disclosures Outline RV response to increased afterload Echo assessment of RV function

More information

Pulmonary Arterial Hypertension (PAH) Treatments

Pulmonary Arterial Hypertension (PAH) Treatments Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health

More information

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University

More information

What is controversial in diagnostic imaging?

What is controversial in diagnostic imaging? Controversies in the management of pulmonary hypertension What is controversial in diagnostic imaging? G. Derumeaux Lyon University Hospices Civils de Lyon France Déclaration de Relations Professionnelles

More information

Class Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension

Class Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Clinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16

Clinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar

More information

different phenotypes

different phenotypes Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes

More information

Blood Pressure in Exercise Prof. Dr. Alfred Hager

Blood Pressure in Exercise Prof. Dr. Alfred Hager Blood Pressure in Exercise Prof. Dr. Alfred Hager Department of Pediatric Cardiology and Congenital Heart Disease Head of Outpatient Section Head of Exercise Laboratory Member of DGPK Guideline Committee

More information

Pulmonary Hypertension Drugs

Pulmonary Hypertension Drugs Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs

More information

Progress in PAH. Gerald Simonneau

Progress in PAH. Gerald Simonneau Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of

More information

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis? Aortic Stenosis in the Elderly: Difficulties for the Clinician Are Symptoms Due to Aortic Stenosis? Raphael Rosenhek Department of Cardiology Medical University of Vienna No disclosure European Society

More information

Information contained in this listing is collected and maintained by the American Board of Internal Medicine.

Information contained in this listing is collected and maintained by the American Board of Internal Medicine. 1936-1940 1936 1937 1938 1939 1940 Decade Internal Medicine 27 209 90 227 255 808 1941-1950 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 Decade Internal Medicine 242 204 342 271 314 473 654 486 335

More information

Pulmonary hypertension in sarcoidosis

Pulmonary hypertension in sarcoidosis Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France

More information

Role of pulmonary vasodilators in the Fontan setting. Michael Cheung Melbourne

Role of pulmonary vasodilators in the Fontan setting. Michael Cheung Melbourne Role of pulmonary vasodilators in the Fontan setting Michael Cheung Melbourne Fontan circuit Low resistance to adequate pulmonary blood flow is critical Central PA anatomy (size and distortion) Intrapulmonary

More information

EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH

EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH Possible solutions for a feasible, global study M. Bacchi, A. Morganti, P. Cornelisse, J. Bolognese, C. Lesage, A. Kümmel, P. Nilsson Copyright 2016 Actelion Pharmaceuticals

More information

Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children

Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children Circ J 2007; 71: 1785 1790 Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children Tomotaka Nakayama, MD; Hiromitsu Shimada,

More information

INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)

INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) N. S. Hill; J. P. Feldman; S. Sahay; D. J. Levine; R. F. Roscigno;

More information

Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension

Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension Respiratory Medicine (2013) 107, 458e465 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction

More information

Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension

Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066

More information

Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ

Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm

More information

National Institute for Health and Clinical Excellence. Drugs for the treatment of pulmonary arterial hypertension

National Institute for Health and Clinical Excellence. Drugs for the treatment of pulmonary arterial hypertension Comments on the draft scope: second consultation October 2006 Drugs for the treatment of pulmonary arterial hypertension Section Consultees Comments Action Background information Actelion Pharmaceuticals

More information

Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension

Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension Original Article Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension Béatrice Bonello 1, Sébastien Renard 2, Julien Mancini 3,

More information

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled

More information

Clinical History. CHD-PAH Case: Physical Exam. Clinical History. To Repair or not to Repair?

Clinical History. CHD-PAH Case: Physical Exam. Clinical History. To Repair or not to Repair? CHD-PAH Case: To Repair or not to Repair? Erika Berman Rosenzweig, MD Columbia University, College of Physicians and Surgeons Clinical History 18 year old female had been previously well, but new murmur

More information

Real life management of CTEPH: patient case

Real life management of CTEPH: patient case 2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens

More information

Dr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A.

Dr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A. (6) EFFECT OF ORAL SILDENAFIL ON RESIDUAL PULMONARY ARTERIAL HYPERTENSION IN PATIENTS FOLLOWING SUCCESSFUL PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY (PBMV): SHORT TERM RESULTS IN 12 PATIENTS. Dr. J. R.

More information

What is controversial in adult congenital heart disease

What is controversial in adult congenital heart disease What is controversial in adult congenital heart disease Gerhard-Paul Diller Adult Congenital Heart Center and Center for Pulmonary Hypertension, Royal Brompton Hospital, London, UK, National Heart Institute,

More information

Πνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015

Πνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015 Πνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015 Γεωργία Γ. Πίτσιου, MD, MSc, PhD Πνευμονολόγος- Εντατικολόγος Επίκουρη Καθηγήτρια Ιατρική Σχολή ΑΠΘ Γ.Ν.

More information

Pulmonary arterial hypertension (PAH) is a. How to detect disease progression in pulmonary arterial hypertension REVIEW

Pulmonary arterial hypertension (PAH) is a. How to detect disease progression in pulmonary arterial hypertension REVIEW Eur Respir Rev 212; 21: 123, 4 47 DOI: 1.1183/95918.911 CopyrightßERS 212 REVIEW How to detect disease progression in pulmonary arterial hypertension J-L. Vachiéry, P. Yerly and S. Huez ABSTRACT: Pulmonary

More information

Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy

Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy Wouter Jacobs, MD, a Anco Boonstra, MD, PhD, a J. Tim Marcus, PhD, b Pieter E. Postmus, MD, PhD, a and Anton Vonk-Noordegraaf,

More information

Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*

Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* CHEST Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* Anna Fijalkowska, MD; Marcin Kurzyna, MD; Adam Torbicki, MD; Grzegorz Szewczyk, MD; Michał

More information

Survival and Predictors of Death in Eisenmenger Syndrome

Survival and Predictors of Death in Eisenmenger Syndrome Survival and Predictors of Death in Eisenmenger Syndrome E. Romeo, M. D'Alto, P. Argiento, B. Sarubbi, G. Scognamiglio, D. Alfano, N. Grimaldi, M.G. Russo, R. Calabrò. Cardiology, Second University of

More information

Bosentan for treatment of pulmonary arterial hypertension (I)

Bosentan for treatment of pulmonary arterial hypertension (I) KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,

More information

Cardiac rehabilitation: a beneficial effect in CHD?

Cardiac rehabilitation: a beneficial effect in CHD? Cardiac rehabilitation: a beneficial effect in CHD? An Van Berendoncks Department of Cardiology Antwerp University Hospital Outline Why exercise training in CHD? Risk and benefits? Feasibility? Why should

More information